Promising Preclinical Data Boosts CERo’s Cancer Research Prospects CERo Therapeutics presented preclinical results showcasing the efficacy of its lead compound, CER-1236, in targeting ovarian cancer cells without causing toxicity. The findings, revealed at a recent scientific conference, bolster hopes for broader applications, including lung cancer. Phase 1 trials for hematologic and solid tumors are planned for 2025.3